Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Type | Public | |
Founded | 1998 | |
HQ | Bethesda, MD, US | Map |
Website | nwbio.com |
USD | |
---|---|
Revenue (Q2, 2020) | 2.0k |
Net income (Q2, 2020) | (58.0m) |
EBIT (Q2, 2020) | (7.4m) |
Market capitalization (19-Jan-2021) | 1.2b |
Closing stock price (19-Jan-2021) | 1.4 |
Cash (30-Sept-2020) | 9.3m |
EV | 1.2b |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 10.0k | 330.0k | 120.0k | 137.0k | 400.0k | 582.0k | 194.0k | 391.0k | 291.0k | 236.0k | 157.0k | 159.0k | 68.0k | 88.0k | 148.0k | 132.0k | 278.0k | 453.0k | 339.0k | 581.0k | 593.0k | 570.0k | 2.0k | ||||
Cost of goods sold | |||||||||||||||||||||||||||
Gross profit | 10.0k | 330.0k | 120.0k | 137.0k | |||||||||||||||||||||||
Gross profit Margin, % | 100% | 100% | 100% | 100% |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 6.7m | 1.6m | 37.0k | 430.0k | 111.0k | 373.0k | 2.0m | 2.9m | 12.2m | 8.9m | 1.4m | 3.2m | 19.2m | 5.4m | 11.7m | 2.1m | 802.0k | 1.8m | 22.0k | 1.1m | 198.0k | 1.6m | 248.0k | 16.3m | 6.7m | 2.0m | 764.0k | 6.0m | 9.3m |
Accounts Receivable | 195.0k | ||||||||||||||||||||||||||||
Prepaid Expenses | 69.0k | 170.0k | 79.0k | 260.0k | 186.0k | 39.0k | 363.0k | 138.0k | 147.0k | 177.0k | 167.0k | 666.0k | 978.0k | 950.0k | 1.1m | 1.5m | 785.0k | 923.0k | 797.0k | 1.1m | 931.0k | 838.0k | 870.0k | 2.3m | 2.2m | 2.6m | 2.8m | 2.3m | 2.9m |
Current Assets | 6.8m | 1.8m | 116.0k | 885.0k | 297.0k | 412.0k | 2.3m | 7.5m | 12.4m | 12.4m | 1.6m | 4.7m | 21.2m | 7.1m | 13.5m | 4.5m | 2.3m | 3.2m | 819.0k | 2.1m | 1.1m | 2.4m | 1.1m | 18.6m | 8.9m | 4.6m | 3.6m | 8.2m | 12.2m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (32.8m) | (67.3m) | (65.8m) | (135.6m) | (114.7m) | (80.2m) | (73.1m) | (35.8m) | (20.3m) |
Depreciation and Amortization | 10.0k | 14.0k | 11.0k | 11.0k | 56.0k | 189.0k | 439.0k | 1.3m | 21.0k |
Accounts Payable | 1.4m | 577.0k | 766.0k | 5.0m | 3.9m | 1.0m | 501.0k | (436.0k) | 30.0k |
Cash From Operating Activities | (14.7m) | (22.8m) | (37.8m) | (54.6m) | (78.6m) | (55.7m) | (36.5m) | (34.6m) | (31.9m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | -0.2 x |
Northwest Biotherapeutics has 2.28k Twitter Followers. The number of followers has increased 0.8% month over month and increased 3% quarter over quarter
F
50/100
F
10/100
When was Northwest Biotherapeutics founded?
Northwest Biotherapeutics was founded in 1998.
Who are Northwest Biotherapeutics key executives?
Northwest Biotherapeutics's key executives are Les Goldman, Marnix L. Bosch and Alton L. Boynton.
How many employees does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 17 employees.
What is Northwest Biotherapeutics revenue?
Latest Northwest Biotherapeutics annual revenue is $2.4 m.
What is Northwest Biotherapeutics revenue per employee?
Latest Northwest Biotherapeutics revenue per employee is $141.8 k.
Who are Northwest Biotherapeutics competitors?
Competitors of Northwest Biotherapeutics include OncoResponse, Karyopharm Therapeutics and LiPlasome Pharma.
Where is Northwest Biotherapeutics headquarters?
Northwest Biotherapeutics headquarters is located at 4800 Montgomery Ln, Bethesda.
Where are Northwest Biotherapeutics offices?
Northwest Biotherapeutics has an office in Bethesda.
How many offices does Northwest Biotherapeutics have?
Northwest Biotherapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies